Synairgen plc services

Synairgen`s primary focus is the development of its inhaled interferon-beta product SNG001, to meet the urgent need for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.